IMBRUVICA for Chronic Lymphocytic Leukemia
1 Views
administrator
07/08/23
IMBRUVICA® (ibrutinib) is developed and commercialized by Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc. This drug also was awarded the prestigious Prix Galien 2015 Award for Best Pharmaceutical Agent and one of the best-selling drugs in 2020 with the sales of $9,442,000,000.
-
Category
Show more
Facebook Comments
No comments found